last year 1st 4 months sales were $368m. so if we assume 30% growth then an acceptable number would be $470m or so.
Assume they maintain similar growth for the year we should see full year sales of $1.7b or about 3% higher than analysts forecasts. At $1.7 b they have added around $400m of sales and $225m of cash flow. or another way to look at it is they have added $150m of EBITDA (ex USA losses). BAL waa acquired at 30x EBITDA. $150m x 30x = $4.5m. in share value they are adding value around $6 per annum. ALLOF IT ENDS UP AS CASH ON BALBCE SHEET
EBITDA harder go guess as it depends on whether they have spent as much as they expected.
- Forums
- ASX - By Stock
- A2M
- 4m 1920FY estimate
4m 1920FY estimate, page-40
-
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add A2M (ASX) to my watchlist
(20min delay)
|
|||||
Last
$6.85 |
Change
-0.030(0.44%) |
Mkt cap ! $4.952B |
Open | High | Low | Value | Volume |
$6.93 | $6.98 | $6.83 | $10.27M | 1.490M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 18844 | $6.84 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$6.85 | 41602 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 11039 | 6.840 |
1 | 3000 | 6.830 |
4 | 17920 | 6.820 |
4 | 9541 | 6.810 |
2 | 5020 | 6.800 |
Price($) | Vol. | No. |
---|---|---|
6.850 | 41602 | 1 |
6.860 | 548 | 1 |
6.870 | 8050 | 3 |
6.880 | 16820 | 3 |
6.890 | 5115 | 2 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
A2M (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online